In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Apollo Endosurgery, Inc.. Trade Record

NYSE:APEN Apollo Endosurgery, Inc. stock gains 11.69% Exit Oct 13, 2017 a Trade Record by priceseries

Trade Chart
Trade Chart APEN Sep 29, 2017, priceSeries
About Apollo Endosurgery, Inc.

Lpath, Inc., a biotechnology company, focuses on the discovery and development of lipidomic-based therapeutic antibodies to treat a range of human diseases in the United States. It develops Lpathomab, a humanized monoclonal antibody (mAb) against lysophosphatidic acid that has completed Phase 1a clinical trial for various chronic pain conditions, including diabetic peripheral neuropathy, post-herpetic neuralgia, chemotherapy-induced neuropathic pain, and pain associated with lumbosacral radiculopathy. The company also develops iSONEP, a mAb against sphingosine-1-phosphate, which is in Phase II clinical trial for the treatment of wet age-related macular degeneration; and ASONEP, a systemic formulation of sonepcizumab and a mAb against the bioactive lipid sphingosine-1-phosphate (S1P), which is in Phase IIa clinical trial to treat kidney cancer, leukemia, prostate cancer, neuroblastoma, lung cancer, pancreatic cancer, and melanoma. Lpath, Inc. has a collaboration agreement with Pfizer Inc. to develop and commercialize iSONEP. Lpath, Inc. is based in San Diego, California.

Trade Information
Trade Type
Entry Date
Sep 29, 2017
Entry Price
Sell Date
Oct 13, 2017
Sell Price
Net Gain
Hold Time
10 Trading Days